Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity

Launched by MACKAY MEMORIAL HOSPITAL · Dec 26, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how effective a combination of two medications, solifenacin and mirabegron, is compared to using solifenacin along with vaginal estrogen cream for women who experience detrusor overactivity. Detrusor overactivity is a condition where the bladder muscles contract too often, leading to frequent and urgent needs to urinate. The trial is currently looking for women who have not found relief from their symptoms with just one medication.

To be eligible for this study, participants need to have been diagnosed with detrusor overactivity and should not have had success with anti-muscarinic medications alone. However, women who have certain health conditions, such as narrow-angle glaucoma or a history of specific cancers, cannot participate. Those who join the trial will receive either the combination of solifenacin and mirabegron or solifenacin with vaginal estrogen cream and will be monitored for their symptoms and overall health. This study aims to find out which treatment works better in helping manage bladder issues for women.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with anti-muscarinics were enrolled for prospective study.
• Exclusion Criteria:
• • Postvoid urine retention before treatment
• • Women who had medical illness and contraindication for using solifenacin and mirabegron, such as narrow-angle glaucoma and hypertension
• • Concerns for using estrogen include: Women with history of cerebrovascular disease; thromboembolic disorders; gallbladder disease; known or suspected breast carcinoma; estrogen-dependent neoplasm or undiagnosed abnormal genital bleeding.
• • Women who were on hormone replacement therapy within 3 months were also excluded from the study